Important Note This article is for educational purposes only. It does not constitute medical advice. Both semaglutide and tirzepatide are prescription medicines and should only be used under medical supervision.
Semaglutide and tirzepatide are two of the most discussed medicines in the field of weight management and type 2 diabetes. While they belong to the same broad category of incretin-based therapies, they work in slightly different ways and have shown different results in clinical studies.
This page provides a direct, evidence-based comparison between the two.
How They Differ in Mechanism
Both medicines mimic gut hormones that help regulate appetite and blood sugar, but they target different receptors:
| Medicine | Type | Receptors Targeted | Key Difference |
|---|---|---|---|
| Semaglutide | GLP-1 agonist | GLP-1 only | Focuses on one pathway |
| Tirzepatide | Dual agonist | GLP-1 + GIP | Targets two pathways |
Tirzepatide’s additional action on the GIP receptor is believed to enhance its effects on appetite and metabolism beyond what semaglutide achieves by targeting GLP-1 alone.
Weight Loss Results in Clinical Trials
One of the most noticeable differences between the two medicines is the amount of weight loss observed in studies:
| Medicine | Highest Reported Average Weight Loss | Trial Duration | Notes |
|---|---|---|---|
| Semaglutide | ~15–20% | 68–72 weeks | Strong results in STEP trials |
| Tirzepatide | ~20–22% | 72 weeks | Generally higher weight loss than semaglutide in available comparisons |
In studies where the two medicines were compared (either directly or indirectly), tirzepatide has consistently shown greater average weight loss than semaglutide. However, individual results can vary significantly depending on dose, adherence, diet, and other factors.
Effects on Blood Sugar
Both semaglutide and tirzepatide are effective at lowering blood sugar in people with type 2 diabetes. Tirzepatide has shown slightly greater reductions in HbA1c (a measure of long-term blood sugar control) in head-to-head studies, likely due to its dual mechanism of action.
Side Effects
Both medicines commonly cause gastrointestinal side effects, especially during the first few weeks or when the dose is increased. These include:
- Nausea
- Vomiting
- Diarrhoea
- Constipation
In general, the side effect profiles are quite similar. Some studies suggest that tirzepatide may cause slightly more gastrointestinal side effects at higher doses, but many people tolerate both medicines well with proper dose escalation.
Discontinuation rates due to side effects are relatively low for both medicines when doses are increased gradually.
Dosing and Administration
| Medicine | Dosing Frequency | Administration | Dose Escalation |
|---|---|---|---|
| Semaglutide | Once weekly | Injection | Gradual |
| Tirzepatide | Once weekly | Injection | Gradual |
Both are given as once-weekly injections and follow a similar approach of starting at a low dose and slowly increasing it to reduce side effects.
Current Status in the United Kingdom (as of 2026)
| Medicine | Approved for Type 2 Diabetes | Approved for Weight Management | Available on NHS |
|---|---|---|---|
| Semaglutide | Yes (Ozempic) | Yes (Wegovy) | Yes (with criteria) |
| Tirzepatide | Yes (Mounjaro) | Yes | Yes (with criteria) |
Both medicines are currently approved and available in the UK for appropriate patients.
Which One Is More Effective?
Based on current research:
- Tirzepatide has shown greater average weight loss and slightly better blood sugar reduction compared to semaglutide in available studies.
- Semaglutide has a longer track record, very strong cardiovascular outcome data, and remains highly effective for many people.
- Individual response varies — some people may respond better to one medicine than the other.
There is no single “best” option for everyone. The choice between semaglutide and tirzepatide depends on a person’s medical history, treatment goals, tolerance, and guidance from their healthcare provider.
Summary
Semaglutide and tirzepatide are both effective once-weekly injectable medicines used for type 2 diabetes and weight management. Tirzepatide targets two hormone pathways (GLP-1 and GIP), while semaglutide targets only GLP-1. Clinical studies have shown that tirzepatide generally produces greater average weight loss than semaglutide. Both medicines have similar side effect profiles, mainly involving the digestive system. As of 2026, both are approved and available in the UK under specific clinical criteria.
References
- ClinicalTrials.gov – STEP Programme (Semaglutide) and SURMOUNT Programme (Tirzepatide).
- Jastreboff, A.M. et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine.
- Wilding, J.P.H. et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine.
- Frias, J.P. et al. (various years). Head-to-head studies comparing semaglutide and tirzepatide. The Lancet and related publications.
- Medicines and Healthcare products Regulatory Agency (MHRA) – Guidance on GLP-1 and dual agonists.
For more context, read our main guide on Semaglutide and our comparison of Retatrutide vs Semaglutide vs Tirzepatide.You can explore research peptide options on PeptidesX.uk
Last Updated: July 2026